医療診断における人工知能(AI)市場:コンポーネント(ソフトウェア、サービス)、アプリケーション(生体内、放射線、神経、CT、MRI、X線、IVD)、エンドユーザー(病院、画像診断センター、診断ラボ)別 - 2027年までの世界市場予測Artificial Intelligence (AI) in Medical Diagnostics Market by Component (Software, Service), Application (In Vivo, Radiology, Neurology, CT, MRI, X - ray, IVD), End User (Hospital, Diagnostic Imaging Center, Diagnostic Laboratory) - Global Forecast to 2027 医療診断におけるAIの世界市場は、2022年の10億米ドルから2027年には55億米ドルに達し、予測期間中に39.9%のCAGRで推移すると予測されています。医療診断におけるAIの採用は、AIベースの技術の導入を促進するため... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー医療診断におけるAIの世界市場は、2022年の10億米ドルから2027年には55億米ドルに達し、予測期間中に39.9%のCAGRで推移すると予測されています。医療診断におけるAIの採用は、AIベースの技術の導入を促進するための様々な政府のイニシアチブの増加、作業負荷を軽減するための放射線科医によるAIソリューションの利用増加、ビッグデータの流入、AIベースのスタートアップに提供される資金、業界を超えたパートナーシップとコラボレーションの増加などの要因によって速いペースで成長している。しかし、訓練されたAI労働力の不足、不安定な規制、これらのソリューションの採用に対する医療従事者の消極性は、市場成長を抑制する要因になると予想されます。 "ソフトウェア部門は予測期間中に最も高い成長率を示すと予想される" 医療診断におけるAI市場は、コンポーネントベースで、ソフトウェアとサービスに区分される。2021年には、サービス分野が市場を支配し、ソフトウェア分野は予測期間中に高いCAGRで成長すると推定される。ソフトウェアソリューションは、人手不足や画像スキャン量の増加といった課題にもかかわらず、医療機関が競争力を獲得することを支援します。 "医療診断におけるAIの世界市場において、生体内診断セグメントが最大のシェアを占める" 医療診断におけるAI市場は、アプリケーションに基づいて、in vivo診断とin vitro診断に区分されます。2021年にこの市場で最大のシェアを占めたのは、in vivo診断セグメントであった。このセグメントの大きなシェアは、これらのソリューションが一貫してヒューマンエラーの削減と治療効果の向上に役立つため、開業医によるAIソリューションの取り込みが増加していることに起因している可能性があります。 "病院セグメントは、予測期間中に最も高いCAGRで成長すると予想される" 医療診断におけるAI市場は、エンドユーザーに基づいて、病院、画像診断センター、診断研究所、およびその他のエンドユーザーに区分されます。病院セグメントは、2021年にこの市場の最大のシェアを指揮しました。このセグメントの大きなシェアは、病院で行われる画像診断治療手順の数の増加、放射線科患者ワークフローの自動化とデジタル化に傾く病院、患者ケアの質を向上させるための病院での低侵襲手順の採用の増加、ワークフロー改善のための高度画像モダリティの適用の増加に起因するものであると考えられる。 "2021年、医療診断市場のAIは北米が支配する" 2021年、北米が最大の市場シェアを占めました。しかし、アジア太平洋地域は予測期間中に42.6%の高いCAGRを記録すると予測されます。アジア太平洋市場の高い成長率は、主に企業が新興市場で採用している成長戦略、高設備の医療診断インフラ、老人人口の増加、癌の有病率の上昇、政府の有利なイニシアチブの実施に起因している可能性があります。 供給側の一次面接の内訳、企業タイプ別、呼称別、地域別。 - 企業タイプ別企業タイプ別:Tier1 (40%)、Tier2 (30%)、Tier3 (30%) - 役職別Cレベル(27%)、ディレクターレベル(18%)、その他(55%) - 地域別北米 (40%)、欧州 (20%)、アジア太平洋 (30%)、RoW (10%) 本市場における主なプレイヤーは、Microsoft(米国)、NVIDIA(米国)、IBM(米国)、Intel Corporation(米国)、Google, Inc.(米国)、Prognos Health(米国)、Nanox AI(イスラエル)、Viz.ai, Inc(米国)、Quibin(スペイン)、Qure.ai(インド)、Therapixel(フランス)、Aidoc(イスラエル)、Koninklijke Philips N.V.(オランダ)、Lunit.Inc.(韓国)、EchoNous Inc. 調査対象範囲 - 本レポートでは、医療診断市場におけるAIをコンポーネント、アプリケーション、エンドユーザー、地域別に調査し - 市場成長に影響を与える要因(ドライバー、阻害要因、機会、課題など)を分析しています。 - ステークホルダー向けに市場の機会や課題を評価し、市場リーダー向けに競争環境の詳細を提供しています - 医療診断市場の成長動向、展望、AI全体への貢献に関して、ミクロ市場を調査しています。 - 5つの主要地域に関して、市場セグメントの収益を予測しています。 レポート購入の主なメリット 本レポートは、この市場のリーダー/新規参入者が、市場全体とサブセグメントの収益数値の最も近い近似値に関する情報を得るのに役立ちます。本レポートは、利害関係者が競争環境を理解し、より良いビジネスの位置づけと適切な市場参入戦略を計画するためのより多くの洞察を得るのに役立ちます。また、本レポートは、医療診断市場におけるAIの鼓動を理解し、主要な市場促進要因、阻害要因、課題、機会に関する情報をステークホルダーに提供します。 目次1 INTRODUCTION 241.1 STUDY OBJECTIVES 24 1.2 MARKET DEFINITION 24 1.3 INCLUSIONS & EXCLUSIONS 25 1.3.1 INCLUSIONS AND EXCLUSIONS 25 1.4 MARKETS COVERED 26 FIGURE 1 AI IN MEDICAL DIAGNOSTICS MARKET SEGMENTATION 26 1.4.1 YEARS CONSIDERED 26 1.5 CURRENCY CONSIDERED 27 1.6 LIMITATIONS 27 1.6.1 SCOPE-RELATED LIMITATIONS 27 1.6.2 METHODOLOGY-RELATED LIMITATIONS 27 1.7 STAKEHOLDERS 27 1.8 SUMMARY OF CHANGES 28 2 RESEARCH METHODOLOGY 29 2.1 RESEARCH DATA 29 FIGURE 2 RESEARCH DESIGN 29 2.1.1 SECONDARY DATA 30 2.1.1.1 Key data from secondary sources 30 2.1.2 PRIMARY DATA 31 FIGURE 3 PRIMARY SOURCES 32 2.1.2.1 Key industry insights 32 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 33 2.2 MARKET SIZE ESTIMATION 33 FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 33 FIGURE 6 MARKET SIZE ESTIMATION 34 TABLE 1 FACTOR ANALYSIS 35 FIGURE 7 AI IN MEDICAL DIAGNOSTICS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022–2027) 36 FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 37 FIGURE 9 TOP-DOWN APPROACH 37 2.3 MARKET DATA ESTIMATION AND TRIANGULATION 38 FIGURE 10 DATA TRIANGULATION METHODOLOGY 38 2.4 STUDY ASSUMPTIONS 39 2.5 RISK ASSESSMENT 39 TABLE 2 RISK ASSESSMENT: AI IN MEDICAL DIAGNOSTICS MARKET 39 3 EXECUTIVE SUMMARY 40 FIGURE 11 AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2022 VS. 2027 (USD MILLION) 40 FIGURE 12 AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 41 FIGURE 13 AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 41 FIGURE 14 GEOGRAPHICAL SNAPSHOT OF AI IN MEDICAL DIAGNOSTICS MARKET 42 4 PREMIUM INSIGHTS 43 4.1 AI IN MEDICAL DIAGNOSTICS MARKET OVERVIEW 43 FIGURE 15 RISING VOLUME OF DIAGNOSTIC IMAGING PROCEDURES AND INFLUX OF BIG DATA TO DRIVE MARKET 43 4.2 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION AND COUNTRY (2021) 44 FIGURE 16 IN VIVO DIAGNOSTICS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICA IN 2021 44 4.3 AI IN MEDICAL DIAGNOSTICS MARKET SHARE, BY APPLICATION, 2022 VS. 2027 44 FIGURE 17 IN VIVO DIAGNOSTICS TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD 44 4.4 AI IN MEDICAL DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 45 FIGURE 18 ASIA PACIFIC REGION TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 45 5 MARKET OVERVIEW 46 5.1 INTRODUCTION 46 FIGURE 19 AI IN MEDICAL DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 46 5.1.1 DRIVERS 47 5.1.1.1 Influx of big data 47 5.1.1.2 Growing number of cross-industry partnerships & collaborations 47 5.1.1.3 Increasing demand for AI-based solutions to reduce work pressure on radiologists 48 5.1.1.4 Rising government initiatives to drive AI-based technologies 48 5.1.1.5 Availability of funding for AI-based startups 49 5.1.2 RESTRAINTS 49 5.1.2.1 Reluctance among medical practitioners to adopt AI-based technologies 49 5.1.2.2 Inadequate AI workforce and ambiguous regulatory guidelines for medical software 50 5.1.3 OPPORTUNITIES 50 5.1.3.1 Untapped emerging markets 50 5.1.3.2 Growing potential of AI in imaging diagnostics for COVID-19 51 5.1.3.3 Increasing focus on developing human-aware AI systems 51 5.1.4 CHALLENGES 51 5.1.4.1 Budgetary constraints 51 5.1.4.2 Unstructured healthcare data 52 5.1.4.3 Data privacy concerns 52 5.1.4.4 Limited interoperability for AI solutions 52 5.2 VALUE CHAIN ANALYSIS 53 FIGURE 20 AI IN MEDICAL DIAGNOSTICS MARKET: VALUE CHAIN 53 5.3 CASE STUDIES 53 5.3.1 FOCUS ON IMPROVING WORKFLOW EFFICACY AND REDUCING BURDEN ON RADIOLOGISTS 53 TABLE 3 USE CASE 1: REDUCING BURDEN ON RADIOLOGISTS BY DEVELOPING AND TESTING AN AI MODEL TO READ LARGE ULTRASOUND DATA 53 5.3.2 IMPROVED TRIAGE 54 TABLE 4 USE CASE 2: PRECISION DRIVEN HEALTH DEVELOPED ML-MODEL TO IMPROVE WORK TRIAGE OF CARDIOLOGISTS (2019) 54 5.4 ECOSYSTEM COVERAGE 54 FIGURE 21 AI IN MEDICAL DIAGNOSTICS: ECOSYSTEM 54 5.5 TECHNOLOGY ANALYSIS 55 TABLE 5 TECHNOLOGICAL DEVELOPMENTS BY LEADING VENDORS 55 5.6 REGULATIONS 56 5.6.1 HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT OF 1996 (HIPAA) 56 5.6.2 HEALTH INFORMATION TECHNOLOGY FOR ECONOMIC AND CLINICAL HEALTH ACT OF 2009 (HITECH) 56 5.6.3 CONSUMER PRIVACY PROTECTION ACT OF 2017 56 5.6.4 NATIONAL CYBERSECURITY PROTECTION ADVANCEMENT ACT OF 2015 56 5.6.5 FUTURE OF LIFE INSTITUTE’S ASILOMAR AI PRINCIPLES 56 5.6.6 THE EUROPEAN MEDICAL DEVICES REGULATION (EU) 2017/745 AND IN-VITRO DIAGNOSTIC MEDICAL DEVICES REGULATION (EU) 2017/746, IN COMBINATION WITH GENERAL DATA PROTECTION REGULATION 2016/679 56 5.6.7 CYBERSECURITY LAW OF PEOPLE'S REPUBLIC OF CHINA 57 5.7 PORTER’S FIVE FORCES ANALYSIS 57 TABLE 6 AI IN MEDICAL DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 57 5.8 INDUSTRY TRENDS 58 5.8.1 ARTIFICIAL INTELLIGENCE IN HEALTHCARE 58 5.8.1.1 Key to AI in Healthcare: Data 58 5.8.1.2 AR and MR in Healthcare Settings 58 5.8.1.3 Healthcare Privacy and Security in 2022 58 5.9 PRICING ANALYSIS 59 5.10 KEY CONFERENCES AND EVENTS (2022−2023) 59 TABLE 7 AI IN MEDICAL DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 59 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 60 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 60 FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 60 TABLE 8 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR END USERS 60 5.11.2 BUYING CRITERIA 61 FIGURE 23 KEY BUYING CRITERIA FOR END USERS 61 TABLE 9 KEY BUYING CRITERIA FOR END USERS 61 6 ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT 62 6.1 INTRODUCTION 63 TABLE 10 AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 63 6.2 SOFTWARE 63 6.2.1 USE OF AI PLATFORMS IN SOFTWARE TO ENHANCE DECISION-MAKING AND SIMPLIFY WORKFLOWS 63 TABLE 11 AI IN MEDICAL DIAGNOSTICS SOFTWARE MARKET, BY REGION, 2020–2027 (USD MILLION) 64 6.3 SERVICES 64 6.3.1 RISING NEED FOR DEPLOYMENT & INTEGRATION OF AI SYSTEMS TO SUPPORT MARKET GROWTH 64 TABLE 12 AI IN MEDICAL DIAGNOSTICS SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 64 7 ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION 65 7.1 INTRODUCTION 66 TABLE 13 AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 66 7.2 IN VIVO DIAGNOSTICS 66 TABLE 14 AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION) 66 7.2.1 IN VIVO DIAGNOSTIC APPLICATIONS MARKET, BY SPECIALTY 67 TABLE 15 AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 67 7.2.1.1 Radiology 67 7.2.1.1.1 AI-based diagnostic tools to reduce work pressure on radiologists 67 TABLE 16 AI IN MEDICAL DIAGNOSTICS FOR IN VIVO RADIOLOGY, BY REGION, 2020–2027 (USD MILLION) 68 7.2.1.2 Cardiology 68 7.2.1.2.1 Rising complexities associated with CVD to drive market 68 TABLE 17 AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO CARDIOLOGY, BY REGION, 2020–2027 (USD MILLION) 68 7.2.1.3 Neurology 69 7.2.1.3.1 Increasing prevalence of critical brain disorders to drive market 69 TABLE 18 AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO NEUROLOGY, BY REGION, 2020–2027 (USD MILLION) 69 7.2.1.4 Obstetrics/Gynecology 70 7.2.1.4.1 Rising use of minimally invasive techniques in gynecology procedures to drive market 70 TABLE 19 AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO OBSTETRICS/GYNECOLOGY, BY REGION, 2020–2027 (USD MILLION) 70 7.2.1.5 Ophthalmology 70 7.2.1.5.1 Rising need for early detection & prevention of eye diseases to drive market 70 TABLE 20 AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO OPHTHALMOLOGY, BY REGION, 2020–2027 (USD MILLION) 71 7.2.1.6 Other specialties 71 TABLE 21 AI IN MEDICAL DIAGNOSTICS MARKET FOR OTHER SPECIALTIES, BY REGION, 2020–2027 (USD MILLION) 71 7.2.2 IN VIVO DIAGNOSTIC APPLICATIONS MARKET, BY MODALITY 72 TABLE 22 AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 72 7.2.2.1 Computed tomography 72 7.2.2.1.1 Rising availability of cardiac CT devices enabled with AI solutions to drive market 72 TABLE 23 AI IN MEDICAL DIAGNOSTICS MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2020–2027 (USD MILLION) 73 7.2.2.2 X-ray 73 7.2.2.2.1 Innovative AI solutions for x-ray imaging by key players to drive market 73 TABLE 24 AI IN MEDICAL DIAGNOSTICS MARKET FOR X-RAY, BY REGION, 2020–2027 (USD MILLION) 73 7.2.2.3 Magnetic resonance imaging (MRI) 74 7.2.2.3.1 Rising technological advancements to drive adoption of AI in MRI 74 TABLE 25 AI IN MEDICAL DIAGNOSTICS MARKET FOR MAGNETIC RESONANCE IMAGING, BY REGION, 2020–2027 (USD MILLION) 74 7.2.2.4 Ultrasound 74 7.2.2.4.1 Increasing prevalence of ovarian cancer to drive market demand 74 TABLE 26 AI IN MEDICAL DIAGNOSTICS MARKET FOR ULTRASOUND, BY REGION, 2020–2027 (USD MILLION) 75 7.2.2.5 Other modalities 75 TABLE 27 AI IN MEDICAL DIAGNOSTICS MARKET FOR OTHER MODALITIES, BY REGION, 2020–2027 (USD MILLION) 75 7.3 IN VITRO DIAGNOSTICS 76 7.3.1 INCREASING ADOPTION OF POINT-OF-CARE TESTING IN EMERGING ECONOMIES TO SUPPORT MARKET GROWTH 76 TABLE 28 AI IN MEDICAL DIAGNOSTICS FOR IN VITRO DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION) 76 8 ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET, BY END USER 77 8.1 INTRODUCTION 78 TABLE 29 AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 78 8.2 HOSPITALS 78 8.2.1 INSTALLATION OF ADVANCED AI DIAGNOSTIC IMAGING SOLUTIONS TO DRIVE MARKET 78 TABLE 30 AI IN MEDICAL DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION) 79 8.3 DIAGNOSTIC IMAGING CENTERS 79 8.3.1 GROWING NUMBER OF PRIVATE IMAGING CENTERS TO DRIVE MARKET 79 TABLE 31 AI IN MEDICAL DIAGNOSTICS MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION, 2020–2027 (USD MILLION) 79 8.4 DIAGNOSTIC LABORATORIES 80 8.4.1 RISING SPECIMEN TEST VOLUME TO DRIVE MARKET 80 TABLE 32 AI IN MEDICAL DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 80 8.5 OTHER END USERS 80 TABLE 33 AI IN MEDICAL DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION) 80 9 ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET, BY REGION 81 9.1 INTRODUCTION 82 TABLE 34 AI IN MEDICAL DIAGNOSTICS MARKET, BY REGION, 2020–2027 (USD MILLION) 82 9.2 NORTH AMERICA 83 FIGURE 24 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET SNAPSHOT 83 TABLE 35 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 84 TABLE 36 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 84 TABLE 37 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 84 TABLE 38 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 85 TABLE 39 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 85 TABLE 40 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 85 9.2.1 US 86 9.2.1.1 Increasing volume of imaging procedures to drive market growth 86 TABLE 41 US: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 86 TABLE 42 US: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 87 TABLE 43 US: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 87 TABLE 44 US: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 87 TABLE 45 US: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 88 9.2.2 CANADA 88 9.2.2.1 Research grants and improved academics in radiology to drive market growth 88 TABLE 46 CANADA: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 88 TABLE 47 CANADA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 89 TABLE 48 CANADA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 89 TABLE 49 CANADA: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 89 TABLE 50 CANADA: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 90 9.3 EUROPE 90 TABLE 51 EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 90 TABLE 52 EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 91 TABLE 53 EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 91 TABLE 54 EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 91 TABLE 55 EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 92 TABLE 56 EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 92 9.3.1 GERMANY 92 9.3.1.1 Rising government support to drive adoption of AI in medical diagnostics 92 TABLE 57 GERMANY: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 93 TABLE 58 GERMANY: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 93 TABLE 59 GERMANY: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 94 TABLE 60 GERMANY: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 94 TABLE 61 GERMANY: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 94 9.3.2 UK 95 9.3.2.1 Increasing number of radiography procedures to drive market growth 95 TABLE 62 UK: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 95 TABLE 63 UK: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 96 TABLE 64 UK: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 96 TABLE 65 UK: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 96 TABLE 66 UK: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 97 9.3.3 FRANCE 97 9.3.3.1 Availability of funding for companies to enhance AI research in medical imaging 97 TABLE 67 FRANCE: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 98 TABLE 68 FRANCE: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 98 TABLE 69 FRANCE: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 98 TABLE 70 FRANCE: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 99 TABLE 71 FRANCE: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 99 9.3.4 ITALY 99 9.3.4.1 Increasing volume of EHRs and EMRs due to rising geriatric population to drive demand for AI solutions 99 TABLE 72 ITALY: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 100 TABLE 73 ITALY: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 100 TABLE 74 ITALY: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 101 TABLE 75 ITALY: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 101 TABLE 76 ITALY: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 101 9.3.5 REST OF EUROPE 102 TABLE 77 REST OF EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 102 TABLE 78 REST OF EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 102 TABLE 79 REST OF EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 103 TABLE 80 REST OF EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 103 TABLE 81 REST OF EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 103 9.4 ASIA PACIFIC 104 FIGURE 25 ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET SNAPSHOT 104 TABLE 82 ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 105 TABLE 83 ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 105 TABLE 84 ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 105 TABLE 85 ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 106 TABLE 86 ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 106 TABLE 87 ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 106 9.4.1 CHINA 107 9.4.1.1 Rising use of AI in clinical decision-making to drive market 107 TABLE 88 CHINA: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 107 TABLE 89 CHINA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 108 TABLE 90 CHINA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 108 TABLE 91 CHINA: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 108 TABLE 92 CHINA: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 109 9.4.2 JAPAN 109 9.4.2.1 Presence of strong healthcare infrastructure to drive uptake of advanced AI solutions 109 TABLE 93 JAPAN: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 109 TABLE 94 JAPAN: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 110 TABLE 95 JAPAN: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 110 TABLE 96 JAPAN: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 110 TABLE 97 JAPAN: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 111 9.4.3 INDIA 111 9.4.3.1 Favorable government initiatives for R&D investments to drive market for AI 111 TABLE 98 INDIA: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 112 TABLE 99 INDIA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 112 TABLE 100 INDIA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 112 TABLE 101 INDIA: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 113 TABLE 102 INDIA: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 113 9.4.4 REST OF ASIA PACIFIC 113 TABLE 103 REST OF ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 114 TABLE 104 REST OF ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 114 TABLE 105 REST OF ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 114 TABLE 106 REST OF ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 115 TABLE 107 REST OF ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 115 9.5 REST OF THE WORLD 115 9.5.1 RISING INITIATIVES TO STABILIZE HEALTHCARE SYSTEMS TO DRIVE UPTAKE OF AI-BASED TOOLS 115 TABLE 108 REST OF THE WORLD: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 116 TABLE 109 REST OF THE WORLD: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 116 TABLE 110 REST OF THE WORLD: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 116 TABLE 111 REST OF THE WORLD: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 117 TABLE 112 REST OF THE WORLD: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 117 10 COMPETITIVE LANDSCAPE 118 10.1 OVERVIEW 118 10.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN 118 TABLE 113 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS 118 10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 119 FIGURE 26 REVENUE ANALYSIS OF KEY PLAYERS 120 10.4 RANKING OF PLAYERS, 2021 120 FIGURE 27 AI IN MEDICAL DIAGNOSTICS MARKET: RANKING OF KEY COMPANIES (2021) 120 10.5 COMPETITIVE LEADERSHIP MAPPING 121 10.5.1 STARS 121 10.5.2 EMERGING LEADERS 122 10.5.3 PERVASIVE PLAYERS 122 10.5.4 PARTICIPANTS 122 FIGURE 28 AI IN MEDICAL DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING (2021) 123 10.6 COMPETITIVE LEADERSHIP MAPPING (STARTUPS) 124 10.6.1 PROGRESSIVE COMPANIES 124 10.6.2 DYNAMIC COMPANIES 124 10.6.3 RESPONSIVE COMPANIES 124 10.6.4 STARTING BLOCKS 124 FIGURE 29 AI IN MEDICAL DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS (2021) 125 10.7 COMPETITIVE BENCHMARKING 126 TABLE 114 AI IN MEDICAL DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 126 TABLE 115 AI IN MEDICAL DIAGNOSTICS MARKET: APPLICATION FOOTPRINT OF KEY PLAYERS 126 TABLE 116 AI IN MEDICAL DIAGNOSTICS MARKET: REGIONAL FOOTPRINT OF KEY PLAYERS 127 10.8 COMPETITIVE SCENARIO 127 TABLE 117 AI IN MEDICAL DIAGNOSTICS MARKET: PRODUCT LAUNCHES, 2019–2022 127 TABLE 118 KEY DEALS, JANUARY 2019–JULY 2022 129 11 COMPANY PROFILES 134 11.1 KEY PLAYERS 134 (Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)* 11.1.1 MICROSOFT 134 TABLE 119 MICROSOFT: BUSINESS OVERVIEW 134 FIGURE 30 MICROSOFT: COMPANY SNAPSHOT (2021) 135 11.1.2 NVIDIA 138 TABLE 120 NVIDIA: BUSINESS OVERVIEW 138 FIGURE 31 NVIDIA: COMPANY SNAPSHOT 139 11.1.3 IBM 142 TABLE 121 IBM: BUSINESS OVERVIEW 142 FIGURE 32 IBM: COMPANY SNAPSHOT 143 11.1.4 INTEL CORPORATION 146 TABLE 122 INTEL: BUSINESS OVERVIEW 146 FIGURE 33 INTEL: COMPANY SNAPSHOT 147 11.1.5 GOOGLE (SUBSIDIARY OF ALPHABET, INC.) 149 TABLE 123 GOOGLE: BUSINESS OVERVIEW 149 FIGURE 34 GOOGLE: COMPANY SNAPSHOT 150 11.1.6 SIEMENS HEALTHINEERS 152 TABLE 124 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW 152 FIGURE 35 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT 153 11.1.7 GE HEALTHCARE 156 TABLE 125 GE HEALTHCARE: BUSINESS OVERVIEW 156 FIGURE 36 GE HEALTHCARE: COMPANY SNAPSHOT 157 11.1.8 DIGITAL DIAGNOSTICS, INC (FORMERLY KNOWN AS IDX) 159 TABLE 126 DIGITAL DIAGNOSTICS: BUSINESS OVERVIEW 159 11.1.9 XILINX 161 TABLE 127 XILINX: BUSINESS OVERVIEW 161 FIGURE 37 XILINX: COMPANY SNAPSHOT 161 11.1.10 INFORMAI LLC 163 TABLE 128 INFORMAI: BUSINESS OVERVIEW 163 *Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies. 11.2 OTHER PLAYERS 164 11.2.1 HEARTFLOW, INC 164 11.2.2 ENLITIC, INC 164 11.2.3 DAY ZERO DIAGNOSTICS, INC 165 11.2.4 AIDENCE 165 11.2.5 BUTTERFLY NETWORK, INC. 166 11.2.6 PROGNOS HEALTH 166 11.2.7 NANOX AI 167 11.2.8 VIZ.AI, INC 167 11.2.9 QUIBIM 168 11.2.10 QURE.AI 169 11.2.11 THERAPIXEL 169 11.2.12 AIDOC 170 11.2.13 KONINKLIJKE PHILIPS N.V. 170 11.2.14 LUNIT. INC 171 11.2.15 ECHONOUS INC. 171 12 APPENDIX 172 12.1 DISCUSSION GUIDE 172 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 175 12.3 CUSTOMIZATION OPTIONS 177 12.4 RELATED REPORTS 177 12.5 AUTHOR DETAILS 178
SummaryThe global AI in medical diagnostics market is projected to reach USD 5.5 Billion by 2027 from USD 1.0 Billion in 2022, at a CAGR of 39.9% during the forecast period. The adoption of AI in medical diagnostics is growing at a fast pace owing to factors such as rise in various government initiatives to drive the uptake of AI-based technologies, AI solutions being more use by radiologists to reduce workload, the influx of big data, fundings made available for AI-based startups, and the growing number of cross-industry partnerships & collaborations. Table of Contents1 INTRODUCTION 241.1 STUDY OBJECTIVES 24 1.2 MARKET DEFINITION 24 1.3 INCLUSIONS & EXCLUSIONS 25 1.3.1 INCLUSIONS AND EXCLUSIONS 25 1.4 MARKETS COVERED 26 FIGURE 1 AI IN MEDICAL DIAGNOSTICS MARKET SEGMENTATION 26 1.4.1 YEARS CONSIDERED 26 1.5 CURRENCY CONSIDERED 27 1.6 LIMITATIONS 27 1.6.1 SCOPE-RELATED LIMITATIONS 27 1.6.2 METHODOLOGY-RELATED LIMITATIONS 27 1.7 STAKEHOLDERS 27 1.8 SUMMARY OF CHANGES 28 2 RESEARCH METHODOLOGY 29 2.1 RESEARCH DATA 29 FIGURE 2 RESEARCH DESIGN 29 2.1.1 SECONDARY DATA 30 2.1.1.1 Key data from secondary sources 30 2.1.2 PRIMARY DATA 31 FIGURE 3 PRIMARY SOURCES 32 2.1.2.1 Key industry insights 32 FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 33 2.2 MARKET SIZE ESTIMATION 33 FIGURE 5 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 33 FIGURE 6 MARKET SIZE ESTIMATION 34 TABLE 1 FACTOR ANALYSIS 35 FIGURE 7 AI IN MEDICAL DIAGNOSTICS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022–2027) 36 FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 37 FIGURE 9 TOP-DOWN APPROACH 37 2.3 MARKET DATA ESTIMATION AND TRIANGULATION 38 FIGURE 10 DATA TRIANGULATION METHODOLOGY 38 2.4 STUDY ASSUMPTIONS 39 2.5 RISK ASSESSMENT 39 TABLE 2 RISK ASSESSMENT: AI IN MEDICAL DIAGNOSTICS MARKET 39 3 EXECUTIVE SUMMARY 40 FIGURE 11 AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2022 VS. 2027 (USD MILLION) 40 FIGURE 12 AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 41 FIGURE 13 AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 41 FIGURE 14 GEOGRAPHICAL SNAPSHOT OF AI IN MEDICAL DIAGNOSTICS MARKET 42 4 PREMIUM INSIGHTS 43 4.1 AI IN MEDICAL DIAGNOSTICS MARKET OVERVIEW 43 FIGURE 15 RISING VOLUME OF DIAGNOSTIC IMAGING PROCEDURES AND INFLUX OF BIG DATA TO DRIVE MARKET 43 4.2 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION AND COUNTRY (2021) 44 FIGURE 16 IN VIVO DIAGNOSTICS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICA IN 2021 44 4.3 AI IN MEDICAL DIAGNOSTICS MARKET SHARE, BY APPLICATION, 2022 VS. 2027 44 FIGURE 17 IN VIVO DIAGNOSTICS TO CONTINUE TO DOMINATE MARKET DURING FORECAST PERIOD 44 4.4 AI IN MEDICAL DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 45 FIGURE 18 ASIA PACIFIC REGION TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 45 5 MARKET OVERVIEW 46 5.1 INTRODUCTION 46 FIGURE 19 AI IN MEDICAL DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 46 5.1.1 DRIVERS 47 5.1.1.1 Influx of big data 47 5.1.1.2 Growing number of cross-industry partnerships & collaborations 47 5.1.1.3 Increasing demand for AI-based solutions to reduce work pressure on radiologists 48 5.1.1.4 Rising government initiatives to drive AI-based technologies 48 5.1.1.5 Availability of funding for AI-based startups 49 5.1.2 RESTRAINTS 49 5.1.2.1 Reluctance among medical practitioners to adopt AI-based technologies 49 5.1.2.2 Inadequate AI workforce and ambiguous regulatory guidelines for medical software 50 5.1.3 OPPORTUNITIES 50 5.1.3.1 Untapped emerging markets 50 5.1.3.2 Growing potential of AI in imaging diagnostics for COVID-19 51 5.1.3.3 Increasing focus on developing human-aware AI systems 51 5.1.4 CHALLENGES 51 5.1.4.1 Budgetary constraints 51 5.1.4.2 Unstructured healthcare data 52 5.1.4.3 Data privacy concerns 52 5.1.4.4 Limited interoperability for AI solutions 52 5.2 VALUE CHAIN ANALYSIS 53 FIGURE 20 AI IN MEDICAL DIAGNOSTICS MARKET: VALUE CHAIN 53 5.3 CASE STUDIES 53 5.3.1 FOCUS ON IMPROVING WORKFLOW EFFICACY AND REDUCING BURDEN ON RADIOLOGISTS 53 TABLE 3 USE CASE 1: REDUCING BURDEN ON RADIOLOGISTS BY DEVELOPING AND TESTING AN AI MODEL TO READ LARGE ULTRASOUND DATA 53 5.3.2 IMPROVED TRIAGE 54 TABLE 4 USE CASE 2: PRECISION DRIVEN HEALTH DEVELOPED ML-MODEL TO IMPROVE WORK TRIAGE OF CARDIOLOGISTS (2019) 54 5.4 ECOSYSTEM COVERAGE 54 FIGURE 21 AI IN MEDICAL DIAGNOSTICS: ECOSYSTEM 54 5.5 TECHNOLOGY ANALYSIS 55 TABLE 5 TECHNOLOGICAL DEVELOPMENTS BY LEADING VENDORS 55 5.6 REGULATIONS 56 5.6.1 HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT OF 1996 (HIPAA) 56 5.6.2 HEALTH INFORMATION TECHNOLOGY FOR ECONOMIC AND CLINICAL HEALTH ACT OF 2009 (HITECH) 56 5.6.3 CONSUMER PRIVACY PROTECTION ACT OF 2017 56 5.6.4 NATIONAL CYBERSECURITY PROTECTION ADVANCEMENT ACT OF 2015 56 5.6.5 FUTURE OF LIFE INSTITUTE’S ASILOMAR AI PRINCIPLES 56 5.6.6 THE EUROPEAN MEDICAL DEVICES REGULATION (EU) 2017/745 AND IN-VITRO DIAGNOSTIC MEDICAL DEVICES REGULATION (EU) 2017/746, IN COMBINATION WITH GENERAL DATA PROTECTION REGULATION 2016/679 56 5.6.7 CYBERSECURITY LAW OF PEOPLE'S REPUBLIC OF CHINA 57 5.7 PORTER’S FIVE FORCES ANALYSIS 57 TABLE 6 AI IN MEDICAL DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 57 5.8 INDUSTRY TRENDS 58 5.8.1 ARTIFICIAL INTELLIGENCE IN HEALTHCARE 58 5.8.1.1 Key to AI in Healthcare: Data 58 5.8.1.2 AR and MR in Healthcare Settings 58 5.8.1.3 Healthcare Privacy and Security in 2022 58 5.9 PRICING ANALYSIS 59 5.10 KEY CONFERENCES AND EVENTS (2022−2023) 59 TABLE 7 AI IN MEDICAL DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS 59 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 60 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 60 FIGURE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR END USERS 60 TABLE 8 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR END USERS 60 5.11.2 BUYING CRITERIA 61 FIGURE 23 KEY BUYING CRITERIA FOR END USERS 61 TABLE 9 KEY BUYING CRITERIA FOR END USERS 61 6 ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT 62 6.1 INTRODUCTION 63 TABLE 10 AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 63 6.2 SOFTWARE 63 6.2.1 USE OF AI PLATFORMS IN SOFTWARE TO ENHANCE DECISION-MAKING AND SIMPLIFY WORKFLOWS 63 TABLE 11 AI IN MEDICAL DIAGNOSTICS SOFTWARE MARKET, BY REGION, 2020–2027 (USD MILLION) 64 6.3 SERVICES 64 6.3.1 RISING NEED FOR DEPLOYMENT & INTEGRATION OF AI SYSTEMS TO SUPPORT MARKET GROWTH 64 TABLE 12 AI IN MEDICAL DIAGNOSTICS SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 64 7 ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION 65 7.1 INTRODUCTION 66 TABLE 13 AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 66 7.2 IN VIVO DIAGNOSTICS 66 TABLE 14 AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION) 66 7.2.1 IN VIVO DIAGNOSTIC APPLICATIONS MARKET, BY SPECIALTY 67 TABLE 15 AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 67 7.2.1.1 Radiology 67 7.2.1.1.1 AI-based diagnostic tools to reduce work pressure on radiologists 67 TABLE 16 AI IN MEDICAL DIAGNOSTICS FOR IN VIVO RADIOLOGY, BY REGION, 2020–2027 (USD MILLION) 68 7.2.1.2 Cardiology 68 7.2.1.2.1 Rising complexities associated with CVD to drive market 68 TABLE 17 AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO CARDIOLOGY, BY REGION, 2020–2027 (USD MILLION) 68 7.2.1.3 Neurology 69 7.2.1.3.1 Increasing prevalence of critical brain disorders to drive market 69 TABLE 18 AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO NEUROLOGY, BY REGION, 2020–2027 (USD MILLION) 69 7.2.1.4 Obstetrics/Gynecology 70 7.2.1.4.1 Rising use of minimally invasive techniques in gynecology procedures to drive market 70 TABLE 19 AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO OBSTETRICS/GYNECOLOGY, BY REGION, 2020–2027 (USD MILLION) 70 7.2.1.5 Ophthalmology 70 7.2.1.5.1 Rising need for early detection & prevention of eye diseases to drive market 70 TABLE 20 AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO OPHTHALMOLOGY, BY REGION, 2020–2027 (USD MILLION) 71 7.2.1.6 Other specialties 71 TABLE 21 AI IN MEDICAL DIAGNOSTICS MARKET FOR OTHER SPECIALTIES, BY REGION, 2020–2027 (USD MILLION) 71 7.2.2 IN VIVO DIAGNOSTIC APPLICATIONS MARKET, BY MODALITY 72 TABLE 22 AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 72 7.2.2.1 Computed tomography 72 7.2.2.1.1 Rising availability of cardiac CT devices enabled with AI solutions to drive market 72 TABLE 23 AI IN MEDICAL DIAGNOSTICS MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2020–2027 (USD MILLION) 73 7.2.2.2 X-ray 73 7.2.2.2.1 Innovative AI solutions for x-ray imaging by key players to drive market 73 TABLE 24 AI IN MEDICAL DIAGNOSTICS MARKET FOR X-RAY, BY REGION, 2020–2027 (USD MILLION) 73 7.2.2.3 Magnetic resonance imaging (MRI) 74 7.2.2.3.1 Rising technological advancements to drive adoption of AI in MRI 74 TABLE 25 AI IN MEDICAL DIAGNOSTICS MARKET FOR MAGNETIC RESONANCE IMAGING, BY REGION, 2020–2027 (USD MILLION) 74 7.2.2.4 Ultrasound 74 7.2.2.4.1 Increasing prevalence of ovarian cancer to drive market demand 74 TABLE 26 AI IN MEDICAL DIAGNOSTICS MARKET FOR ULTRASOUND, BY REGION, 2020–2027 (USD MILLION) 75 7.2.2.5 Other modalities 75 TABLE 27 AI IN MEDICAL DIAGNOSTICS MARKET FOR OTHER MODALITIES, BY REGION, 2020–2027 (USD MILLION) 75 7.3 IN VITRO DIAGNOSTICS 76 7.3.1 INCREASING ADOPTION OF POINT-OF-CARE TESTING IN EMERGING ECONOMIES TO SUPPORT MARKET GROWTH 76 TABLE 28 AI IN MEDICAL DIAGNOSTICS FOR IN VITRO DIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION) 76 8 ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET, BY END USER 77 8.1 INTRODUCTION 78 TABLE 29 AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 78 8.2 HOSPITALS 78 8.2.1 INSTALLATION OF ADVANCED AI DIAGNOSTIC IMAGING SOLUTIONS TO DRIVE MARKET 78 TABLE 30 AI IN MEDICAL DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION) 79 8.3 DIAGNOSTIC IMAGING CENTERS 79 8.3.1 GROWING NUMBER OF PRIVATE IMAGING CENTERS TO DRIVE MARKET 79 TABLE 31 AI IN MEDICAL DIAGNOSTICS MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION, 2020–2027 (USD MILLION) 79 8.4 DIAGNOSTIC LABORATORIES 80 8.4.1 RISING SPECIMEN TEST VOLUME TO DRIVE MARKET 80 TABLE 32 AI IN MEDICAL DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 80 8.5 OTHER END USERS 80 TABLE 33 AI IN MEDICAL DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION) 80 9 ARTIFICIAL INTELLIGENCE IN MEDICAL DIAGNOSTICS MARKET, BY REGION 81 9.1 INTRODUCTION 82 TABLE 34 AI IN MEDICAL DIAGNOSTICS MARKET, BY REGION, 2020–2027 (USD MILLION) 82 9.2 NORTH AMERICA 83 FIGURE 24 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET SNAPSHOT 83 TABLE 35 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 84 TABLE 36 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 84 TABLE 37 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 84 TABLE 38 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 85 TABLE 39 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 85 TABLE 40 NORTH AMERICA: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 85 9.2.1 US 86 9.2.1.1 Increasing volume of imaging procedures to drive market growth 86 TABLE 41 US: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 86 TABLE 42 US: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 87 TABLE 43 US: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 87 TABLE 44 US: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 87 TABLE 45 US: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 88 9.2.2 CANADA 88 9.2.2.1 Research grants and improved academics in radiology to drive market growth 88 TABLE 46 CANADA: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 88 TABLE 47 CANADA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 89 TABLE 48 CANADA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 89 TABLE 49 CANADA: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 89 TABLE 50 CANADA: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 90 9.3 EUROPE 90 TABLE 51 EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 90 TABLE 52 EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 91 TABLE 53 EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 91 TABLE 54 EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 91 TABLE 55 EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 92 TABLE 56 EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 92 9.3.1 GERMANY 92 9.3.1.1 Rising government support to drive adoption of AI in medical diagnostics 92 TABLE 57 GERMANY: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 93 TABLE 58 GERMANY: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 93 TABLE 59 GERMANY: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 94 TABLE 60 GERMANY: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 94 TABLE 61 GERMANY: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 94 9.3.2 UK 95 9.3.2.1 Increasing number of radiography procedures to drive market growth 95 TABLE 62 UK: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 95 TABLE 63 UK: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 96 TABLE 64 UK: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 96 TABLE 65 UK: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 96 TABLE 66 UK: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 97 9.3.3 FRANCE 97 9.3.3.1 Availability of funding for companies to enhance AI research in medical imaging 97 TABLE 67 FRANCE: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 98 TABLE 68 FRANCE: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 98 TABLE 69 FRANCE: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 98 TABLE 70 FRANCE: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 99 TABLE 71 FRANCE: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 99 9.3.4 ITALY 99 9.3.4.1 Increasing volume of EHRs and EMRs due to rising geriatric population to drive demand for AI solutions 99 TABLE 72 ITALY: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 100 TABLE 73 ITALY: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 100 TABLE 74 ITALY: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 101 TABLE 75 ITALY: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 101 TABLE 76 ITALY: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 101 9.3.5 REST OF EUROPE 102 TABLE 77 REST OF EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 102 TABLE 78 REST OF EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 102 TABLE 79 REST OF EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 103 TABLE 80 REST OF EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 103 TABLE 81 REST OF EUROPE: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 103 9.4 ASIA PACIFIC 104 FIGURE 25 ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET SNAPSHOT 104 TABLE 82 ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 105 TABLE 83 ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 105 TABLE 84 ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 105 TABLE 85 ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 106 TABLE 86 ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 106 TABLE 87 ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 106 9.4.1 CHINA 107 9.4.1.1 Rising use of AI in clinical decision-making to drive market 107 TABLE 88 CHINA: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 107 TABLE 89 CHINA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 108 TABLE 90 CHINA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 108 TABLE 91 CHINA: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 108 TABLE 92 CHINA: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 109 9.4.2 JAPAN 109 9.4.2.1 Presence of strong healthcare infrastructure to drive uptake of advanced AI solutions 109 TABLE 93 JAPAN: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 109 TABLE 94 JAPAN: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 110 TABLE 95 JAPAN: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 110 TABLE 96 JAPAN: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 110 TABLE 97 JAPAN: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 111 9.4.3 INDIA 111 9.4.3.1 Favorable government initiatives for R&D investments to drive market for AI 111 TABLE 98 INDIA: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 112 TABLE 99 INDIA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 112 TABLE 100 INDIA: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 112 TABLE 101 INDIA: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 113 TABLE 102 INDIA: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 113 9.4.4 REST OF ASIA PACIFIC 113 TABLE 103 REST OF ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 114 TABLE 104 REST OF ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 114 TABLE 105 REST OF ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 114 TABLE 106 REST OF ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 115 TABLE 107 REST OF ASIA PACIFIC: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 115 9.5 REST OF THE WORLD 115 9.5.1 RISING INITIATIVES TO STABILIZE HEALTHCARE SYSTEMS TO DRIVE UPTAKE OF AI-BASED TOOLS 115 TABLE 108 REST OF THE WORLD: AI IN MEDICAL DIAGNOSTICS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 116 TABLE 109 REST OF THE WORLD: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY SPECIALTY, 2020–2027 (USD MILLION) 116 TABLE 110 REST OF THE WORLD: AI IN MEDICAL DIAGNOSTICS MARKET FOR IN VIVO DIAGNOSTICS, BY MODALITY, 2020–2027 (USD MILLION) 116 TABLE 111 REST OF THE WORLD: AI IN MEDICAL DIAGNOSTICS MARKET, BY COMPONENT, 2020–2027 (USD MILLION) 117 TABLE 112 REST OF THE WORLD: AI IN MEDICAL DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 117 10 COMPETITIVE LANDSCAPE 118 10.1 OVERVIEW 118 10.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN 118 TABLE 113 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS 118 10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 119 FIGURE 26 REVENUE ANALYSIS OF KEY PLAYERS 120 10.4 RANKING OF PLAYERS, 2021 120 FIGURE 27 AI IN MEDICAL DIAGNOSTICS MARKET: RANKING OF KEY COMPANIES (2021) 120 10.5 COMPETITIVE LEADERSHIP MAPPING 121 10.5.1 STARS 121 10.5.2 EMERGING LEADERS 122 10.5.3 PERVASIVE PLAYERS 122 10.5.4 PARTICIPANTS 122 FIGURE 28 AI IN MEDICAL DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING (2021) 123 10.6 COMPETITIVE LEADERSHIP MAPPING (STARTUPS) 124 10.6.1 PROGRESSIVE COMPANIES 124 10.6.2 DYNAMIC COMPANIES 124 10.6.3 RESPONSIVE COMPANIES 124 10.6.4 STARTING BLOCKS 124 FIGURE 29 AI IN MEDICAL DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS (2021) 125 10.7 COMPETITIVE BENCHMARKING 126 TABLE 114 AI IN MEDICAL DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 126 TABLE 115 AI IN MEDICAL DIAGNOSTICS MARKET: APPLICATION FOOTPRINT OF KEY PLAYERS 126 TABLE 116 AI IN MEDICAL DIAGNOSTICS MARKET: REGIONAL FOOTPRINT OF KEY PLAYERS 127 10.8 COMPETITIVE SCENARIO 127 TABLE 117 AI IN MEDICAL DIAGNOSTICS MARKET: PRODUCT LAUNCHES, 2019–2022 127 TABLE 118 KEY DEALS, JANUARY 2019–JULY 2022 129 11 COMPANY PROFILES 134 11.1 KEY PLAYERS 134 (Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)* 11.1.1 MICROSOFT 134 TABLE 119 MICROSOFT: BUSINESS OVERVIEW 134 FIGURE 30 MICROSOFT: COMPANY SNAPSHOT (2021) 135 11.1.2 NVIDIA 138 TABLE 120 NVIDIA: BUSINESS OVERVIEW 138 FIGURE 31 NVIDIA: COMPANY SNAPSHOT 139 11.1.3 IBM 142 TABLE 121 IBM: BUSINESS OVERVIEW 142 FIGURE 32 IBM: COMPANY SNAPSHOT 143 11.1.4 INTEL CORPORATION 146 TABLE 122 INTEL: BUSINESS OVERVIEW 146 FIGURE 33 INTEL: COMPANY SNAPSHOT 147 11.1.5 GOOGLE (SUBSIDIARY OF ALPHABET, INC.) 149 TABLE 123 GOOGLE: BUSINESS OVERVIEW 149 FIGURE 34 GOOGLE: COMPANY SNAPSHOT 150 11.1.6 SIEMENS HEALTHINEERS 152 TABLE 124 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW 152 FIGURE 35 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT 153 11.1.7 GE HEALTHCARE 156 TABLE 125 GE HEALTHCARE: BUSINESS OVERVIEW 156 FIGURE 36 GE HEALTHCARE: COMPANY SNAPSHOT 157 11.1.8 DIGITAL DIAGNOSTICS, INC (FORMERLY KNOWN AS IDX) 159 TABLE 126 DIGITAL DIAGNOSTICS: BUSINESS OVERVIEW 159 11.1.9 XILINX 161 TABLE 127 XILINX: BUSINESS OVERVIEW 161 FIGURE 37 XILINX: COMPANY SNAPSHOT 161 11.1.10 INFORMAI LLC 163 TABLE 128 INFORMAI: BUSINESS OVERVIEW 163 *Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies. 11.2 OTHER PLAYERS 164 11.2.1 HEARTFLOW, INC 164 11.2.2 ENLITIC, INC 164 11.2.3 DAY ZERO DIAGNOSTICS, INC 165 11.2.4 AIDENCE 165 11.2.5 BUTTERFLY NETWORK, INC. 166 11.2.6 PROGNOS HEALTH 166 11.2.7 NANOX AI 167 11.2.8 VIZ.AI, INC 167 11.2.9 QUIBIM 168 11.2.10 QURE.AI 169 11.2.11 THERAPIXEL 169 11.2.12 AIDOC 170 11.2.13 KONINKLIJKE PHILIPS N.V. 170 11.2.14 LUNIT. INC 171 11.2.15 ECHONOUS INC. 171 12 APPENDIX 172 12.1 DISCUSSION GUIDE 172 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 175 12.3 CUSTOMIZATION OPTIONS 177 12.4 RELATED REPORTS 177 12.5 AUTHOR DETAILS 178
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(SaaS(Software as a Service))の最新刊レポート
MarketsandMarkets社のSaaS(Software as a Service)分野での最新刊レポート
本レポートと同じKEY WORD(artificial)の最新刊レポート
よくあるご質問MarketsandMarkets社はどのような調査会社ですか?マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/21 10:26 156.13 円 165.08 円 200.38 円 |